3D Contrast Enhanced Acoustic Perfusion Imaging in Adult After Subarachnoid Hemorrhage

Launched by UNIVERSITY HOSPITAL, CAEN · Jan 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new, non-invasive device that uses advanced ultrasound technology to help doctors see the major arteries in the brain for patients who have experienced a specific type of stroke called aneurysmal subarachnoid hemorrhage (SAH). This condition can lead to serious complications, and traditional imaging methods like CT scans or MRIs often require moving critically ill patients, which can be risky. The goal of the trial is to determine if this bedside device can safely and effectively detect these important blood vessels without the need for transport.

To participate in the trial, individuals must be at least 18 years old, admitted to the neurology intensive care unit for an aneurysmal SAH, and have a suitable area on their head for the ultrasound. However, there are some exclusions, such as those with allergies to the ultrasound contrast agent, severe high blood pressure, or who are pregnant. Participants will have the opportunity to contribute to important research that may improve care for future patients with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Admitted in neurologic ICU of the CHU Caen, Normandy, for a subarachnoid hemorrhage of the anterior circulation.
• • Usable ultrasound temporal window.
• • 18 years old and more.
• • Consent of the participant or the trusted person.
• Exclusion Criteria:
• • non-aneurysmal subarachnoid haemorrhage.
• • Contraindication to ultrasound contrast agent Sonovue, including allergies to a compound.
• • Uncontrolled systemic hypertension.
• • Acute respiratory distress syndrome.
• • Pregnancy or breastfeeding mother.
• • Vulnerable person with guardianship or curatorship.
• • Patient not affiliated to french social security system (Sécurité Sociale)